Blinatumomab after transplant for high-risk B-ALL patients
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 25 or younger when you enroll
- You have B-ALL and your bone marrow test shows no measurable remaining leukemia (MRD negative below 0.01%), or you meet a specific “higher risk” condition (like certain relapse patterns or MRD slightly above 0.01% at a key treatment time)
- A matching donor is available (unrelated or haploidentical donor)
- You must be well enough to travel through treatment (heart, lung, kidney, and liver function limits, and no major breathing problems at rest)
- You must already be enrolled in the sponsor’s “Blinatumomab Bridging Therapy (BBT) Trial”
- You must not have active infection that is not improving, and you cannot be pregnant or breastfeeding; effective birth control is required during treatment and for 2 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that uses blinatumomab (a drug that helps your immune system attack leukemia cells) combined with your own stem cell transplant. It is for people with B-ALL who cannot or choose not to have a transplant from another person.
This trial tests whether three targeted medicines (decitabine, venetoclax, and blinatumomab) can help prevent leukemia from coming back after a stem cell transplant. It is for people with B-cell ALL who have no detectable remaining leukemia cells and are at least 3 months past transplant.
This trial tests a drug called blinatumomab, given after a stem cell transplant, to help prevent leukemia from coming back in people with high-risk B-cell acute lymphoblastic leukemia. It may help keep the cancer in remission for longer.
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
This trial tests adding a drug called blinatumomab plus a low-dose donor lymphocyte infusion (DLI) as maintenance therapy after stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL). It aims to reduce the chance of the cancer coming back.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.